SCHEMBL22901903

SCHEMBL22901903

CC(CS)NC(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.63
ALDH1A1 P00352 2/20 0.63
HPGD P15428 1/20 0.63
SMN1; SMN2 Q16637 4/20 0.58
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
HTT P42858 1/20 0.58
CTRB1 P17538 1/20 0.58
NPC1 O15118 3/20 0.55
HSP90AA1 P07900 1/20 0.51
PPARG P37231 1/20 0.51
PPARA Q07869 1/20 0.51
TP53 P04637 1/20 0.49
LMNA P02545 2/20 0.48
GPR139 Q6DWJ6 1/20 0.47
GAA P10253 1/20 0.47
ACACB O00763 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29137460 0.85 RAB9A (0.67) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL3380039 0.83 RAB9A (0.65) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL8526512 0.83 RAB9A (0.87) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL12019757 0.83 RAB9A (0.65) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL799431 0.83 RAB9A (0.87) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL8507346 0.83 RAB9A (0.87) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL4821933 0.81 RAB9A (0.63) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL13753268 0.81 MLYCD (0.64) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL5612318 0.81 HPGD (0.68) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL7670820 0.81 RAB9A (0.63) RAB9AALDH1A1HPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11033635-B2 Antibody-STING agonist conjugates and their use in immunotherapy IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-06-15 US disclosed
US-20210015941-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11033635-B2 Antibody-STING agonist conjugates and their use in immunotherapy STING1, CGAS, MAVS RAB9A 1132/4885ALDH1A1 4589/4885HPGD 3490/4885
US-20210015941-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY STING1, CGAS, MAVS RAB9A 1132/4885ALDH1A1 4589/4885HPGD 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.